Form 4: Celldex Therapeutics Director Cheryl Cohen Granted 16,500 Stock Options Under Equity Plan

Celldex Therapeutics, Inc. director Cheryl Cohen was granted 16,500 non-qualified stock options with an exercise price of $19.53, exercisable from June 5, 2026, and expiring on June 5, 2035.

Summary

• Cheryl Cohen, a Director of Celldex Therapeutics, Inc. (CLDX), was granted 16,500 non-qualified stock options.
• The options have an exercise price of $19.53 per share.
• These options become exercisable on June 5, 2026, and will expire on June 5, 2035.
• The grant was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard compensation practices that align director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The options are part of the company's established 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• No direct negatives are apparent from this specific option grant, as it represents a standard compensation event.

Risks

• The value of the options is dependent on the future stock price of Celldex Therapeutics, Inc. exceeding the exercise price of $19.53, meaning the options could expire worthless if the stock price does not appreciate sufficiently.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports a past compensation event.

Industry Context

This specific Form 4 filing, detailing an option grant to a director, is a routine compensation disclosure within the biotechnology and pharmaceutical industry. Such grants are common practice to attract and retain talent and align management interests with shareholder value, reflecting standard corporate governance practices rather than specific industry trends.

Comparison to Industry Standards

• The grant of 16,500 stock options to a director is a common form of non-cash compensation in the biotechnology sector, similar to practices at companies like BioNTech SE (BNTX) or Moderna, Inc. (MRNA) which frequently use equity incentives to compensate their board members and executives.
• The exercise price of $19.53 is set at the market price on the grant date, which is standard for non-qualified stock options.
• The vesting period (exercisable after one year) and a 10-year expiration period are also typical for such grants in the industry, aiming to provide long-term incentives.

Corporate Governance

Related Party Transactions

• The grant of 16,500 non-qualified stock options to Cheryl Cohen, a Director of Celldex Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders by incentivizing long-term stock price appreciation. However, it also represents potential future dilution if the options are exercised.
• Employees: No direct impact on general employees is indicated by this specific filing, though similar equity incentive plans may apply to other employees.

Next Steps

• The options will become exercisable on June 5, 2026, at which point the director may choose to exercise them if the stock price is favorable.
• The options will remain valid until their expiration date of June 5, 2035.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, Cheryl Cohen